CAJ | 학술논문

贫血在肺癌患者中常见,其重要原因是由化疗所致.贫血可以引起乏力、心动过速等症状,影响患者的生活质量及疗效,导致生存时间缩短,被认为是判断预后的独立因素.输注红细胞、使用促红细胞生成类药物是目前治疗肺癌患者贫血的主要措施.在血红蛋白水平明显下降之前,以促红细胞生成类药物治疗为主,尽量减少输血次数,将血红蛋白水平维持在10.0～12.0 g/dl之间,可改善患者生活质量,同时有效防止血栓形成等不良事件的发生.
빈혈재폐암환자중상견,기중요원인시유화료소치.빈혈가이인기핍력、심동과속등증상,영향환자적생활질량급료효,도치생존시간축단,피인위시판단예후적독립인소.수주홍세포、사용촉홍세포생성류약물시목전치료폐암환자빈혈적주요조시.재혈홍단백수평명현하강지전,이촉홍세포생성류약물치료위주,진량감소수혈차수,장혈홍단백수평유지재10.0～12.0 g/dl지간,가개선환자생활질량,동시유효방지혈전형성등불량사건적발생.
Anemia is commonly observed in lung cancer patients,and it is mainly caused by chemotherapy.Anemia can cause several debilitating symptoms such as fatigue and tachycardia which will not only influence the patients' quality of life and therapy effect,but also short the survival time.So anemia has been regarded as a poor independent prognostic indicator of the disease.Transfusion the erythrocytes and using the erythropoiesis stimulating agents is the main treatments of the disease.Using the erythropoiesis stimulating agents is the main treatment before the hemoglobin decreasing significantly in order to reduce the times of transfusion.Keeping the hemoglobin between 10.0-12.0 g/dl can improve the patients' quality of life and avoid the adverse events such as thrombus formation at the same time.